BioSpace News Archive

Policy

EU Vetoes Illumina’s Acquisition of Grail Despite Win in US Court - Updated

The Administrative Law Judge overseeing the FTC’s challenge of Illumina’s acquisition of Grail rejected the regulator’s anti-competition argument, Illumina announced Thursday.

September 2, 2022
·
3 min read
·
Mark Terry
Career Advice

A Guide to Working at the FDA: Benefits, Challenges and Tips From Former Employees

The best thing a professional can do when considering a position at the FDA is weigh the pros and cons. To help, we’ve created a guide to working at the FDA, with benefits, challenges and tips.

September 2, 2022
·
5 min read
·
Rosemary Scott
Report: Cannabis-Based Products could Undercut Pharmaceutical Profits by Billions

A new report estimates that if cannabis was to be legalized across the United States, it could cut into pharmaceutical sales by billions of dollars.

September 2, 2022
·
2 min read
·
Alex Keown
FDA

FDA Review: Immusoft, BioCryst, Intellia and More

The U.S. Food and Drug Administration had a busy week leading up to the Labor Day holiday. Here’s a look at the agency’s recent activities.

September 2, 2022
·
3 min read
·
Mark Terry
Drug Development

Immusoft Takes First-Ever Engineered B Cell Therapy into Clinic

Immusoft is heading into the clinic with what it claims is the first engineered B cell gene therapy cleared for in-human study, the company announced Thursday.

September 2, 2022
·
3 min read
·
Alex Keown
Study Opens Door to New Class of Melanoma Therapeutics

Researchers found that inhibiting a key metabolic enzyme kills melanoma cells and halts tumor growth, opening the door for a new class of drugs to treat melanoma.

September 2, 2022
·
3 min read
·
Mark Terry
Drug Development

Following Takeda’s Exit, Finch Slashes Headcount, Pauses Trial

Finch announced that it is slashing its headcount by around 37% and suspending its planned Phase I study in autism a week after Takeda withdrew from its multi-year collaboration.

September 2, 2022
·
2 min read
·
Tristan Manalac
Drug Development

Clinical Catch-Up: Vertex, BI, MannKind and More Share Updates

It’s been a busy week for research on rare diseases, with several clinical trials from AnaptysBio, Regenxbio, Sangamo and more posting results from ongoing activities.

September 2, 2022
·
5 min read
·
Vanessa Doctor, RN and Alex Keown
Drug Development

Boehringer Bags First FDA Approval for Rare Skin Disease

Boehringer announced that the FDA approved Spevigo for generalized pustular psoriasis flares in adults, the first drug approved for this indication.

September 2, 2022
·
2 min read
·
Tristan Manalac
Biotech Bay

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference

Sight Sciences, Inc. (Nasdaq: SGHT) an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced plans to participate in the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.

September 2, 2022
·
1 min read